🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Phyllodes tumors of the Breast

Dr Sameer Rastogi AIIMS, New Delhi 🇮🇳 Memorial Sloan Kettering Cancer Center Rashi Kapoor Sorun Shishak Desmoid Tumor Research Foundation CR Chandrasekar Desmoid Foundation ONLUS - Italia Desmoid Canada Bharath B G ecancer We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/science/sorast…

Thank you OncoDaily ! Thanks Ghazal Tansir Bharath B G ecancer !

So proud of Sydney Stern, PhD, MS for beautifully presenting the data on pediatric #TGCT at #ASCO25. Great to see lots of interest in our poster! 🙌🏼

Organised 264 th #sarcoma #supportgroup meeting today where Dr Subhash gave educational session on Dealing with Comorbidities like diabetes, hypertension, thyroid problems caused during the treatment. Thank you for addressing the concerns of the patients #awareness #companionship

#ASCO25, pimicotinib led to significant ORR via RECIST 1.1 was 54% at Week 25, exciting potential option for patients with #TGCT

TGCT Support A promising drug with a strong safety profile and great patient manageability. Looking forward to adding it to our therapeutic armamentarium soon! TGCT Support

MANEUVER study results presented at ASCO 2025, Sarcoma Oral Session. Pimicotinib was able to induce 54% RECIST and 61.9% volumetric responses in patients with symptomatic TGCT. Honoured to be part of this study #ASCO2025 #TGCT #sarcoma

Brilliant presentation of the placebo-controlled Ph3 trial MANEUVER by Dr Gelderblom. CSF1R inhibitor Pimicotinib provided statistically significant/clinically meaningful improvement in pain and functionality for #TGCT pts, with manageable toxicity profile (and no signs of

An interesting trial of anlotinib + epirubicin vs epiribicin in metastatic STS. Promising combination but low ORR (3%) with single agent raises questions about which subtypes were studied. #ASCO24

Interesting data with camrelizumab +apatinib in chordoma. Great to see activity in #chordoma #ASCO25

Exciting initial activity of TDXd in DSRCT. #ASCO25

⭐️🚨Delighted to report 👉🏼Efficacy and safety of pralsetinib in RET fusion-positive solid tumors: Final data from the ARROW trial. | Journal of Clinical Oncology #RET #TissueAgnostic #PrecisionMedicine OncoAlert G Curigliano MD PhD ASCO #ASCO25 ascopubs.org/doi/10.1200/JC…

Primary results of RELATIVITY-098 showing that adjuvant nivo+rela does not improve RFS over nivo alone, HR 1.01, biomarker data pointing to value of presence of tumor as a potential requirement for LAG3 blockade to improve efficacy. Neoadjuvant Nivo/rela had >60% MPR

A phyllodes tumor develops in the connective tissue of the breast. This type of tumor is usually fast-growing but hardly ever spreads beyond the breast.    youtu.be/jwq3oedEvYA?si…

Pleased to share Phase 2 trial results for low-dose regorafenib in relapsed synovial sarcoma. N=25, 76% previously exposed to pazopanib. 3-month progression-free rate: 56%. Median progression-free survival: 5 mths. ascopubs.org/doi/10.1200/GO… OncoDaily JCO Global Oncology

Catequentinib improved median PFS to 3.42 months compared to 1.41 months with PBO (HR 0.54; p=0.0265). Results point to catequentinib as effective treatment option for pts with advanced or metastatic leiomyosarcoma. Interview with Robin Lewis Jones👇 ecancer.org/en/video/12413… #ASCO25

Dr Sameer Rastogi JCO Global Oncology Rashi Kapoor Sachin Sarcoma Society Synovial Sarcoma Foundation Sorun Shishak CR Chandrasekar SPAGN Sarcoma UK Robin Lewis Jones Italian Sarcoma Group British Sarcoma Group We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/blog/low-dose-…

Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing